More News

New coalition forms to boost US biotech

Jim Cornall -
The American Biotech Innovation Alliance (ABIA) has announced its launch, bringing together biotechnology leaders from across the US around...

Advancing Aramchol-based therapeutics

Jim Cornall -
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. have announced a collaboration to develop a novel human chronic cardiac fibrosis...

CRISPR inhibits hepatitis E virus

Jim Cornall -
Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. A...

Biotech searches for alternative to Red 40

Jim Cornall -
Debut and Oterra have announced a multi-million-dollar collaboration to develop and scale a natural alternative to artificial red colours...

Antibody spurs nerve fibre regrowth after spinal cord injury

Jim Cornall -
An international research group has shown that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now,...

Basel life sciences supercluster welcomes Korean biopharmas

Jim Cornall -
Basel Area Business & Innovation, the strategic growth partner helping ventures in science and tech to land, launch and...

Study shows IL-23 inhibitor demonstrates efficacy in perianal fistulizing Crohn’s disease

Jim Cornall -
Johnson & Johnson has announced results from its phase 3 FUZION study evaluating TREMFYA (guselkumab) in adults with active...

Hand-held probe maps cancerous tissue

Jim Cornall -
Breast cancer impacts more than 2m women around the world each year. Following radiotherapy or chemotherapy, breast-conserving surgery is...

Cells “back up” DNA replication to survive damage

Jim Cornall -
Every time a cell divides, it must copy its DNA with extreme precision. But this process is constantly challenged...

Base to Base biotech podcast 58: Congenital myotonic dystrophy

Jim Cornall -
This week, we have a conversation with congenital myotonic dystrophy patient advocacy consultant Lisa Harvey-Duren, who was the founding...

Lab-grown red blood cells cover all blood types

admin -
Scarlet Therapeutics has announced a landmark preclinical result: its proprietary cell-line derived, universal, lab-grown red blood cells (RBCs) have...

Researchers discover new therapeutic targets for lithium in Alzheimer’s disease

Jim Cornall -
Lithium chloride may affect many cellular level changes in Alzheimer’s disease, a new study from the University of Eastern...

New research brings personalised treatment for Parkinson’s disease closer

Jim Cornall -
A new study led by researchers from VIB and KU Leuven in Belgium shows that Parkinson’s disease can be...

Greywolf Therapeutics and Genomics look to develop first‑in‑class autoimmune diseases treatments

Jim Cornall -
Genomics has announced a strategic relationship with Greywolf Therapeutics. Under the agreement, Genomics will curate and analyse large-scale genetic...

Priority review for potential first approved treatment for warm autoimmune haemolytic anaemia

Jim Cornall -
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the...

New first-in-class therapy for chronic graft-versus-host disease approved in Australia

Jim Cornall -
Specialised Therapeutics has announced that NIKTIMVO (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration...

Boost in cancer fight as mini-antibodies reactivate p53 protein

Jim Cornall -
Each year, 20m people are diagnosed with cancer. Various organs can be affected, and cancer types differ greatly at...

Scientists discover new way to make drug-resistant cancer treatable

Jim Cornall -
Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most...

KAIST identifies viruses and variants simultaneously by controlling CRISPR speed​

Jim Cornall -
As the spread of infectious diseases accelerates, technologies that can accurately distinguish multiple viruses in a single test are...

Base to Base biotech podcast 57: Keeping drugs cool, and treatment resistant depression

Jim Cornall -
This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher,...

ELREXFIO improves progression-free survival for patients with relapsed or refractory multiple myeloma

Jim Cornall -
Pfizer Inc. has announced positive topline results from the phase 3 MagnetisMM-5 study evaluating ELREXFIO (elranatamab) as monotherapy in...